Share chart HilleVax, Inc.
Extended chart
Simple chart
About HilleVax, Inc.
HilleVax, Inc., биофармацевтическая компания клинической стадии, занимается разработкой и коммерциализацией новых вакцин. Он разрабатывает HIL-214, вакцину-кандидат на основе вирусоподобных частиц для профилактики острого гастроэнтерита средней и тяжелой степени, вызванного норовирусной инфекцией. Штаб-квартира компании находится в Бостоне, штат Массачусетс.Main settings
| IPO date | 2022-04-29 |
|---|---|
| ISIN | US43157M1027 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | link |
| Change price per day: | 0% (1.86) |
|---|---|
| Change price per week: | -7.92% (2.02) |
| Change price per month: | +0.5405% (1.85) |
| Change price per 3 month: | +3.33% (1.8) |
| Change price per half year: | -3.13% (1.92) |
| Change price per year: | -85.32% (12.67) |
| Change price per 3 year: | -81.17% (9.88) |
| Change price per year to date: | 0% (1.86) |
Grade
Underestimation
| Title | Value | Grade |
|---|---|---|
| P/S | 0 | 0 |
| P/BV | 0.6586 | 10 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
|---|---|---|
| ROA, % | -54.84 | 0 |
| ROE, % | -70.13 | 0 |
| ROIC, % | 0 | 0 |
Dividends
| Title | Value | Grade |
|---|---|---|
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
|---|---|---|
| Debt/EBITDA | -0.1579 | 10 |
| Debt/Ratio | 0.1272 | 10 |
| Debt/Equity | 0.2473 | 10 |
Growth impulse
| Title | Value | Grade |
|---|---|---|
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 7294.81 | 10 |
| Yield EPS, % | 2204.68 | 10 |
Main owners
| Institutions | Volume | Share, % |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 9 781 472 | 19.68 |
| Deerfield Management Company, L.P. (Series C) | 4 004 231 | 8.06 |
| Deep Track Capital, LP | 2 900 000 | 5.83 |
| VR Adviser, LLC | 2 075 000 | 4.17 |
| Franklin Resources, Inc. | 1 846 396 | 3.72 |
| Carlyle Group Inc. | 1 838 486 | 3.7 |
| Blackrock Inc. | 1 775 937 | 3.57 |
| Vanguard Group Inc | 1 464 840 | 2.95 |
| T. Rowe Price Investment Management, Inc. | 1 453 790 | 2.93 |
| Catalys Pacific, LLC | 1 308 974 | 2.63 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
|---|---|---|---|
| iShares Morningstar Small-Cap ETF | 0.00081 | 391.25 | 0.25 |
| 0 | 391.25 | 0.25 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Dr. Robert M. Hershberg M.D., Ph.D. | Co-Founder, President, CEO & Chairman of the Board | 1.02M | 1962 (63 years) |
| Dr. Anju Chatterji Ph.D. | Chief Technology Officer | N/A | |
| Mr. Paul S. Bavier J.D. | General Counsel, Secretary & Chief Administrative Officer | N/A | 1972 (53 years) |
| Ms. Astrid Borkowski M.D., Ph.D. | Chief Medical Officer | N/A | 1970 (55 years) |
| Mr. Shane A. Maltbie | CFO & Treasurer | N/A | 1982 (43 years) |
| Mr. Ozzie Berger | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. Aditya Kohli Ph.D. | Co-Founder, Chief Business Officer & Director | 782.44k | 1988 (37 years) |
| Mr. Sean McLoughlin | Chief Operating Officer | N/A | 1972 (53 years) |
About company
Address: United States, Boston. MA, 75 State Street - Open in google maps, Open in yandex maps
Website: https://www.hillevax.com
Website: https://www.hillevax.com
